10 min listen
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
FromShort Wave
ratings:
Length:
10 minutes
Released:
Nov 5, 2021
Format:
Podcast episode
Description
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.Additional links:- Jon's reporting on aducanumab: https://n.pr/3bDV0MY- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqoYou can always reach the show by emailing shortwave@npr.org.
Released:
Nov 5, 2021
Format:
Podcast episode
Titles in the series (100)
Life After Whale Death: What happens after a whale dies? Their carcasses, known as "whale falls," provide a sudden, concentrated source of food for organisms in the deep sea. by Short Wave